Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

INTRODUCTION: Long-term safety data are critical for evaluating therapies for psoriasis. Ixekizumab has demonstrated efficacy and is well tolerated for the treatment of moderate-to-severe plaque psoriasis. We examined the safety and tolerability of up to 5 years of ixekizumab therapy in patients wit...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Dermatol Ther (Heidelb)
Main Authors: Armstrong, April, Paul, Carle, Puig, Luis, Boehncke, Wolf Henning, Freeman, Michael, Torii, Hideshi, Papp, Kim, Griffiths, Christopher E. M., Blauvelt, Andrew, Reich, Kristian, Gooderham, Melinda, Terui, Tadashi, Renda, Lisa, Agada, Noah, Xu, Wen, Gallo, Gaia, Lebwohl, Mark G.
Format: Artigo
Jezik:Inglês
Izdano: Springer Healthcare 2019
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6994584/
https://ncbi.nlm.nih.gov/pubmed/31749092
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13555-019-00340-3
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki